Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer

doi:10.7518/hxkq.2020.05.003

Abstract

Abstract:

Anti-programmed cell death protein 1 (PD-1) monoclonal antibody is a landmark drug in the field of malignant tumor treatment, and its emergence has resulted in the use of immunotherapy in treating various types of malignancies. A large number of clinical studies abroad have shown that it has a more significant effect than traditional strategies in the treatment of advanced head and neck cancer, and it has a significantly lower incidence of adverse events than chemotherapy. Recently, the clinical application of anti-PD-1 monoclonal antibodies in China has changed the traditional treatment mode of head and neck malignant tumors. Immunotherapy has become the first-line treatment option for recurrent/metastatic head and neck cancer. Furthermore, the indications of PD-1 monoclonal antibodies have been continuously expanded through clinical trials, and their biomarkers have been explored and validated. The application of PD-1 monoclonal antibodies tend to be individualized and precise and potentially improves the treatment levels of advanced head and neck malignancies.

Key words: advanced head and neck cancer, anti-programmed cell death protein 1 monoclonal antibody, immunotherapy

CLC Number:

R739.8

Guo Wei. Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer[J]. West China Journal of Stomatology, 2020, 38(5): 489-494.

Figures/Tables 1

References 33

[1]	Cramer JD, Burtness B, Ferris RL . Immunotherapy for head and neck cancer: recent advances and future directions[J]. Oral Oncol, 2019,99:104460. doi: 10.1016/j.oraloncology.2019.104460 URL pmid: 31683169
[2]	Burtness B, Harrington KJ, Greil R , et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019,394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7 URL pmid: 31679945
[3]	Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016,375(19):1856-1867. doi: 10.1056/NEJMoa1602252 URL pmid: 27718784
[4]	Cohen EEW, Soulières D, Le Tourneau C , et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019,393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8 URL pmid: 30509740
[5]	Seiwert TY, Burtness B, Mehra R , et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016,17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3 URL pmid: 27247226
[6]	Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol, 2018,81:45-51. doi: 10.1016/j.oraloncology.2018.04.008 URL pmid: 29884413
[7]	Yearley JH, Gibson C, Yu N , et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer[J]. Clin Cancer Res, 2017,23(12):3158-3167. doi: 10.1158/1078-0432.CCR-16-1761 URL pmid: 28619999
[8]	Rizvi NA, Hellmann MD, Snyder A , et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015,348(6230):124-128. doi: 10.1126/science.aaa1348 URL pmid: 25765070
[9]	Lawrence MS, Stojanov P, Polak P , et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes[J]. Nature, 2013,499(7457):214-218. doi: 10.1038/nature12213 URL pmid: 23770567
[10]	Gameiro SF, Ghasemi F, Barrett JW , et al. Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy[J]. Oncoimmunology, 2018,7(10):e1498439. doi: 10.1080/2162402X.2018.1498439 URL pmid: 30288365
[11]	Harrington KJ, Ferris RL, Blumenschein G Jr , et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial[J]. Lancet Oncol, 2017,18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7 URL pmid: 28651929
[12]	Wang DY, Salem JE, Cohen JV , et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018,4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923 URL pmid: 30242316
[13]	Johnson DB, Balko JM, Compton ML , et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016,375(18):1749-1755. doi: 10.1056/NEJMoa1609214 URL pmid: 27806233
[14]	Di Giacomo AM, Danielli R, Guidoboni M , et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases[J]. Cancer Immunol Immunother, 2009,58(8):1297-1306. doi: 10.1007/s00262-008-0642-y URL pmid: 19139884
[15]	Chiou VL, Burotto M . Pseudoprogression and immune-related response in solid tumors[J]. J Clin Oncol, 2015,33(31):3541-3543. doi: 10.1200/JCO.2015.61.6870 URL pmid: 26261262
[16]	Eisenhauer EA, Therasse P, Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009,45(2):228-247. doi: 10.1016/j.ejca.2008.10.026 URL
[17]	Baxi SS, Dunn LA, Burtness BA . Amidst the excitement: a cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma[J]. Oral Oncol, 2016,62:147-148. doi: 10.1016/j.oraloncology.2016.10.007 URL pmid: 27776933
[18]	Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria[J]. Clin Cancer Res, 2009,15(23):7412-7420. doi: 10.1158/1078-0432.CCR-09-1624 URL pmid: 19934295
[19]	Seymour L, Bogaerts J, Perrone A , et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017,18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8 URL pmid: 28271869
[20]	Tazdait M, Mezquita L, Lahmar J , et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria[J]. Eur J Cancer, 2018,88:38-47. doi: 10.1016/j.ejca.2017.10.017 URL pmid: 29182990
[21]	Le Lay J, Jarraya H, Lebellec L , et al. irRECIST and iRECIST: the devil is in the details[J]. Ann Oncol, 2017,28(7):1676-1678. doi: 10.1093/annonc/mdx168 URL pmid: 28383646
[22]	Xiang JJ, Uy NF, Minja FJ , et al. Hyperprogression after one dose of nivolumab in sinonasal cancer: a case report[J]. Laryngoscope, 2020,130(4):907-910. doi: 10.1002/lary.28042 URL pmid: 31058321
[23]	Champiat S, Dercle L, Ammari S , et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017,23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741 URL pmid: 27827313
[24]	Saâda-Bouzid E, Defaucheux C, Karabajakian A , et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Ann Oncol, 2017,28(7):1605-1611. doi: 10.1093/annonc/mdx178 URL pmid: 28419181
[25]	Keam SJ . Toripalimab: first global approval[J]. Drugs, 2019,79(5):573-578. doi: 10.1007/s40265-019-01076-2 URL pmid: 30805896
[26]	Tang B, Yan X, Sheng X , et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients[J]. J Hematol Oncol, 2019,12(1):7. doi: 10.1186/s13045-018-0693-2 URL pmid: 30642373
[27]	Sheng X, Yan X, Chi Z , et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase Ⅰb trial[J]. J Clin Oncol, 2019,37(32):2987-2999. doi: 10.1200/JCO.19.00210 URL pmid: 31403867
[28]	Wang F, Wei XL, Wang FH , et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ⅰb/Ⅱ clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9):1479-1486. doi: 10.1093/annonc/mdz197 URL pmid: 31236579
[29]	Hoy SM . Sintilimab: first global approval[J]. Drugs, 2019,79(3):341-346. doi: 10.1007/s40265-019-1066-z URL pmid: 30742278
[30]	Markham A, Keam SJ . Camrelizumab: first global approval[J]. Drugs, 2019,79(12):1355-1361. doi: 10.1007/s40265-019-01167-0 URL pmid: 31313098
[31]	Chen X, Ma L, Wang X , et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210[J]. Cancer Biol Med, 2019,16(1):173-181. doi: 10.20892/j.issn.2095-3941.2018.0172 URL pmid: 31119058
[32]	Lin C, Wang S, Xie W , et al. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway[J]. Oncotarget, 2016,7(37):59236-59244. doi: 10.18632/oncotarget.10985 URL pmid: 27494860
[33]	Xu J, Zhang Y, Jia R , et al. Anti-PD-1 Antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019,25(2):515-523. doi: 10.1158/1078-0432.CCR-18-2484 URL pmid: 30348638

姓名	性别	年龄/岁	诊断	用药次数	近期疗效
孙XX	男	52	肺癌舌转移	4	疾病稳定
王X	男	35	右下牙龈黑色素瘤远处转移	1	死亡
熊XX	男	59	左腮腺癌颈部转移	3	死亡
刘XX	女	52	左颌下腺腺样囊性癌肺部转移	6	疾病稳定
宋XX	女	65	下牙龈黏膜黑色素瘤肺部转移	5	疾病稳定
张XX	女	42	颌骨肉瘤术后、放疗后复发	4	疾病进展
陶XX	男	47	腮腺导管癌术后放疗后骨转移	6	疾病进展
尹XX	男	57	颞部鳞状细胞癌多次术后复发	4	完全缓解
徐XX	男	49	鼻腔鼻窦恶性黑色素瘤远处转移	4	疾病稳定
苏XX	女	35	上前牙龈恶性黑色素瘤颈部转移	12	部分缓解